The latter may represent a more aggressive and proliferation-centric tumour phenotype through TP53 mutations affecting directly the cell cycle, while the former could affect indirectly the mitotic rate by regulating the chromatin state through PBRM1 and SETD2 and thereby facilitating access to transcription factors. The gene discussed is SETD2; the disease is neoplasm.